Elsarraj, Hanan Hong, Yan Valdez, Kelli Michaels, Whitney Hook, Marcus Smith, William Chien, Jeremy Herschkowitz, Jason Troester, Melissa Beck, Moriah Inciardi, Marc Gatewood, Jason May, Lisa Cusick, Therese McGinness, Marilee Ricci, Lawrence Fan, Fang Tawfik, Ossama Marks, Jeffrey Knapp, Jennifer Yeh, Hung-Wen Thomas, Patricia Carrasco, D. Fields, Timothy Godwin, Andrew Behbod, Fariba Additional file 5: Figure S2. of Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion BCL9 showed increased nuclear expression, while BCL9L expression remained cytoplasmic during ductal carcinoma in situ (DCIS) invasive transition. A Immunofluorescence staining of BCL9 (red; top panel), BCL9L (red; bottom panel), K5/K19 (green), and Hoechst (blue) in a primary sample that represents: adjacent normal glands (left), DCIS lesions (middle), and invasive ductal carcinoma (IDC) (right). BCL9 and BCL9L are conjugated to Alexa-Fluor 594 (red) and K5/K19 were conjugated to Alexa-Fluor 488 (green). Nuclei were counterstained with Hoechst. Scale bars 50 μm, × 40 objective was used. B, C RT-qPCR of BCL9 and BCL9L mRNA in epithelial cell adhesion molecule (EpCAM)-positive epithelial cells sorted from SUM225 (B) and DCIS.COM (C) mouse intraductal xenograft model (MIND) xenografts at 2, 6, and 10 weeks post-intraductal injection. The bar graphs represent fold change normalized to 2 weeks. Data are mean values ± standard error of the mean (n = 3, *p <0.05). D Representative western blot analysis of cell lysates from control and BCL9-KD-SUM225 and DCIS.COM blotted with anti-BCL9, and anti-BCL9L antibodies. β-actin was used as a loading control. The analysis showed no change in BCL9L protein levels in BCL9-KD cells compared to control cells. (PDF 5012 kb) breast cancer invasion BCL 9;PDF 5012 kb;scale bars 50 μ m;BCL 9L protein levels;SUM;BCL 9-KD cells;IDC;B cell lymphoma -9;DCIS;epithelial cell adhesion molecule;mouse intraductal xenograft model;DCIS.COM;BCL 9L expression;10 weeks post-intraductal injection;BCL 9L mRNA;vivo ductal carcinoma;BCL 9;anti-BCL 9L antibodies;ductal carcinoma 2015-09-17
    https://springernature.figshare.com/articles/journal_contribution/Additional_file_5_Figure_S2_of_Expression_profiling_of_in_vivo_ductal_carcinoma_in_situ_progression_models_identified_B_cell_lymphoma-9_as_a_molecular_driver_of_breast_cancer_invasion/4445384
10.6084/m9.figshare.c.3637697_D11.v1